Since the beginning of March, a large number of companies acting as a collaborator, sponsor, or CRO publically declared disruptions to planned and ongoing clinical trials on SEC filings, press releases and clinical trial registries, as well as on social media. Businesses have delayed commencement of planned trials, with some withdrawing them completely. Furthermore, enrolment has been suspended in ongoing trials, while others have been terminated completely.
The Covid-19 Dashboard on the Pharma Intelligence Center dynamically tracks these interrupted trials from the Clinical Trials Database, as well as the list of companies connected to these trials. Read more here.